The FDA Quality Management System Regulation (QMSR) replaces the legacy Quality System Regulation (21 CFR Part 820) by incorporating ISO 13485:2016 by reference — fundamentally changing how medical device quality systems are regulated in the United States.
What Is FDA QMSR?
The QMSR represents the FDA’s harmonization of U.S. medical device quality system requirements with the internationally recognized ISO 13485:2016 standard. Rather than maintaining a separate, prescriptive set of requirements under 21 CFR Part 820, the FDA now incorporates ISO 13485 by reference and adds specific FDA modifications and additions where U.S. regulatory expectations exceed the base standard.
This transition impacts every medical device manufacturer subject to FDA oversight and requires careful assessment of existing quality systems against the new combined requirements.
What Changed from 21 CFR Part 820
- ISO 13485 by reference — the base QMS requirements now come from ISO 13485:2016
- FDA-specific additions — additional requirements beyond ISO 13485 in areas like CAPA, complaints, and design controls
- Terminology alignment — harmonized language with international standards
- Risk management emphasis — strengthened integration of risk-based thinking throughout the QMS
- Supplier controls — updated expectations for supplier management aligned with ISO 13485
- Document control — aligned with ISO 13485 document and record requirements
Who Is Affected
The QMSR transition affects all organizations subject to FDA medical device regulations:
- U.S.-based medical device manufacturers
- Foreign manufacturers exporting to the U.S.
- Contract manufacturers producing FDA-regulated devices
- Component suppliers to FDA-regulated manufacturers
- Organizations currently certified to ISO 13485 (gap analysis still needed)
- Organizations operating under legacy 21 CFR Part 820
Key Areas Requiring Assessment
Even organizations with existing ISO 13485 certification should assess:
- FDA-specific additions not covered by ISO 13485 alone
- Design control alignment with FDA expectations
- CAPA process rigor against combined requirements
- Complaint handling and MDR reporting integration
- Supplier control updates for QMSR compliance
- Documentation and record-keeping gaps
Transition Timeline and Preparation
Organizations should prepare for the QMSR transition by:
- Conducting a gap analysis — compare current QMS against QMSR requirements (ISO 13485 + FDA additions)
- Updating documentation — align quality manual, procedures, and records with harmonized requirements
- Training personnel — ensure quality and operational teams understand the new framework
- Performing internal audits — verify implementation against QMSR before regulatory inspection
- Assessing suppliers — evaluate supplier controls against updated expectations
- Engaging independent audits — obtain objective assessment of QMSR readiness
How Qualyx Group Supports QMSR Readiness
Our independent audits help organizations assess their quality system against the full scope of QMSR requirements:
- Audits conducted against ISO 13485:2016 plus FDA-specific QMSR additions
- Gap identification between current QMS state and QMSR requirements
- Assessment of both documentation and actual implementation
- Process-focused evaluation that mirrors how FDA inspectors assess systems
- Defensible findings that support transition planning and management decision-making
- No consulting or implementation support — preserving audit independence
ISO 13485:2016
21 CFR Part 820
Gap Analysis
Pre-Inspection Readiness
Preparing for QMSR?
An independent audit against QMSR requirements can identify gaps before your next FDA inspection. Free consultation available.